a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）

NCT07128797 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

NAFLD (Non-alcoholic Fatty Liver Disease)
NASH (Nonalcoholic Steatohepatitis)

Interventions

DRUG: B1344
OTHER: Placebo

Sponsor

Tasly Biopharmaceuticals Co., Ltd.